Finanzen von Affimed NV (AFMD)AFMDAffimed NV

Affimed NV (AFMD) generates its revenue primarily from Collaboration revenue, which accounts for 100.0% of total sales, equivalent to €155.00K. Understanding this concentration is critical for investors evaluating how AFMD navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Affimed NV maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -9214.84%, while the net margin is -9767.10%. These profitability ratios, combined with a Return on Equity (ROE) of -149.48%, provide a clear picture of how effectively AFMD converts its operational activities into shareholder value.

In the context of the broader market, AFMD competes directly with industry leaders such as APDN and SONN. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, AFMD's gross margin of 100.00% stands against APDN's 1.69% and SONN's N/A. Such benchmarking helps identify whether Affimed NV is trading at a premium or discount relative to its financial performance.